MENU MENU

Letter from our CEO on COVID-19

Read More

Explore Deeply. Uncover the Possibilities.

Pioneering innovative therapeutic options
for patients who need them the most.

Learn More

Illuminating Possibilities. Charting Pathways.

Pioneering innovative therapeutic options
for patients who need them the most.

Learn More

Expanding Possibilities.Building Hope.

Pioneering innovative therapeutic options
for patients who need them the most.

Learn More

We create first-in-class medicines to treat chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis, and pancreatic cancer.

Pipeline

We are developing products with the potential to change lives.

Clinical Trials

We are dedicated to responsibly developing groundbreaking therapies for serious and life-threatening diseases.

FibroGen China

We have taken an unprecedented approach to introducing world-class innovations in China.

Press Releases

FibroGen to Report Second Quarter 2020 Financial Results

FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19

FibroGen Appoints Thane Wettig as Chief Commercial Officer

FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress

FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19
View All

FG Culture

“Being surrounded by so many intelligent, kind, and professional people makes FibroGen a wonderful place to work.”

David Gervasi
Associate Scientist II, Cell Biology

Contact Our Company

We are growing a dedicated team committed to innovation and helping patients worldwide.

Contact Us